Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
QGEN
Qiagen N.V.
QIAGEN derives a large portion of revenue from consumables and disposables used with its diagnostic instruments.
|
$10.36B |
$47.58
-1.66%
|
|
BAX
Baxter International Inc.
Novum IQ infusion platform is a medical device platform core to Baxter's Medical Devices & Equipment offerings.
|
$10.33B |
$20.12
-1.23%
|
|
JAZZ
Jazz Pharmaceuticals plc
Zanidatamab is a bispecific antibody, a core oncology modality represented by Bispecific Antibodies.
|
$10.28B |
$169.37
-1.05%
|
|
EHC
Encompass Health Corporation
Encompass Health operates inpatient rehabilitation hospital services, aligning with the Hospital Services investable theme.
|
$10.12B |
$100.50
-2.24%
|
|
HSIC
Henry Schein, Inc.
Henry Schein directly distributes dental equipment to dental practices, aligning with its core product offerings.
|
$9.70B |
$80.02
+2.48%
|
|
RNA
Avidity Biosciences, Inc.
Direct product modality: oligonucleotide therapeutics (AOC platform) delivering RNA payloads.
|
$9.33B |
$72.50
-0.13%
|
|
VRNA
Verona Pharma plc
Verona's Ohtuvayre (ensifentrine) is a small-molecule therapeutic used for COPD management.
|
$9.10B |
$106.91
|
|
AXSM
Axsome Therapeutics, Inc.
Axsome's revenue drivers Auvelity and Sunosi and pipeline products are oral small-molecule therapeutics.
|
$8.85B |
$177.27
+1.80%
|
|
ARWR
Arrowhead Pharmaceuticals, Inc.
Arrowhead's core platform and lead programs are based on RNA interference (siRNA) therapeutics, i.e., RNAi Therapeutics.
|
$8.83B |
$63.85
-3.62%
|
|
BIO
Bio-Rad Laboratories, Inc.
Bio-Rad directly manufactures and sells diagnostic instruments and related equipment used in clinical laboratories.
|
$8.48B |
$313.72
-2.59%
|
|
HALO
Halozyme Therapeutics, Inc.
Halozyme's ENHANZE is a proprietary drug-delivery platform enabling rapid, subcutaneous administration of large-volume biologics.
|
$8.33B |
$71.21
-0.85%
|
|
AVTR
Avantor, Inc.
Avantor provides Laboratory Testing & Advisory Services, aligning with outsourced testing and regulatory support offerings.
|
$8.29B |
$12.16
+1.16%
|
|
BPMC
Blueprint Medicines Corporation
AYVAKIT is Blueprint Medicines' flagship oncology/hematology drug; directly produced and marketed, fitting Biotech - Oncology.
|
$8.27B |
$129.46
|
|
KRYS
Krystal Biotech, Inc.
Krystal Biotech's core HSV-1 gene therapy platform and lead product VYJUVEK directly represent a gene therapy business.
|
$8.25B |
$284.63
+0.93%
|
|
ATR
AptarGroup, Inc.
Aptar markets proprietary drug-delivery platforms (e.g., nasal/inhalation delivery) which are core to its pharma offering.
|
$8.22B |
$124.71
-0.32%
|
|
AHR
American Healthcare REIT, Inc.
Healthcare Services & Facilities: reflects management and operation of healthcare facilities within the portfolio.
|
$8.09B |
$48.01
+0.06%
|
|
LNC
Lincoln National Corporation
LNC provides disability insurance as part of its group protection/employee benefits offerings.
|
$7.75B |
$40.90
-1.51%
|
|
MASI
Masimo Corporation
Primary revenue comes from patient monitoring devices and systems sold to healthcare providers.
|
$7.72B |
$142.12
+1.61%
|
|
NUVL
Nuvalent, Inc.
Nuvalent is a oncology-focused biotechnology company developing targeted cancer therapies (ROS1/ALK inhibitors), fitting Biotech - Oncology.
|
$7.52B |
$104.26
-1.79%
|
|
DVA
DaVita Inc.
DaVita operates clinical laboratory testing facilities and diagnostic services as part of its dialysis and kidney care offerings.
|
$7.49B |
$104.74
-1.04%
|
|
CYTK
Cytokinetics, Incorporated
Cytokinetics' core programs target cardiovascular diseases (aficamten for hypertrophic cardiomyopathy, omecamtiv mecarbil and ulacamten), making 'Cardiovascular Drugs' the primary investable theme.
|
$7.49B |
$62.58
-1.36%
|
|
ABVX
Abivax S.A.
Obefazimod is an oral small-molecule therapeutic targeting inflammatory pathways in IBD.
|
$7.43B |
$116.92
+0.11%
|
|
MTSR
Metsera, Inc.
Metsera is a clinical-stage biotech developing peptide-based therapeutics (MET-097i, MET-233i, MET-97o, MET-224o), i.e., Peptide Therapeutics.
|
$7.41B |
$70.53
+0.04%
|
|
BRKR
Bruker Corporation
Bruker directly manufactures diagnostic instrumentation and analytical equipment such as MALDI Biotyper and other diagnostic/imaging instruments.
|
$7.34B |
$48.40
-2.14%
|
|
GRFS
Grifols, S.A.
Grifols operates as a large, global pharmaceutical company with a core focus on plasma-derived therapies.
|
$7.33B |
$8.89
-0.45%
|
|
VOYA
Voya Financial, Inc.
VOYA provides health insurance products and related stop‑loss/health solutions to employers, a central part of its Workplace Solutions.
|
$7.19B |
$74.55
-4.81%
|
|
HIMS
Hims & Hers Health, Inc.
Laboratory testing & advisory services core to in-house lab capabilities.
|
$7.09B |
$31.43
+0.62%
|
|
BTSG
BrightSpring Health Services, Inc. Common Stock
Company operates home health and hospice services to patients in home and community settings.
|
$6.94B |
$39.20
-1.00%
|
|
GKOS
Glaukos Corporation
The iStent family and related MIGS devices are surgical equipment used in ophthalmic procedures.
|
$6.90B |
$120.30
+5.08%
|
Showing page 6 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
